// App-Quantinova.ai

e16051 : Determining viability of circulating tumor cells (CTCs) as a predictive biomarker for response in patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with Radium 223 (Ra).

Researchers

Presenter

  • Cristina Surez

Principal Investigators

  • Daniel Castellano

  • Jose Angel Arranz Arija

  • Rafael Morales

  • Aranzazu Gonzalez del Alba

  • M Isabel Sez

  • Claudia Aura

  • Begona Mellado

  • Jose Luis Perez-Gracia

  • Josep Puig

  • Joan Carles

  • Maria Jose Mendez-VidAlJose Jimenez

Medical Centers

  • Bioclever, Barcelona, Spain

  • Hospital Universitario Quiron Madrid, Madrid, Spain

  • Hospital Universitario del Mar, Barcelona, Spain

  • Translational Genomics and Targeted Therapeutics in Oncology.IDIBAPS. Medical Oncology Department. Hospital Clinic, Barcelona, Spain

  • Molecular Pathology Group, Vall dHebron Institute of Oncology, VHIO, Barcelona, SpainHospital Clinico Virgen de la Victoria, Malaga, SpainMolecular Pathology Laboratory, Vall dHebron Institute of Oncology, Barcelona, Spain

  • Oncology Department, University Hospital Vall d'Hebron, Barcelona, Spain

  • Hospital Vall d Hebron, Vall d Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Hospital Doce de Octubre, Madrid, Spain

  • University Hospital Reina Sofia, Cordoba, Spain

  • Hospital Universitario Son Espases, Palma de Mallorca, Spain

  • Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved